20% off: Here's why I think the Cochlear (ASX:COH) share price is a buy today

The Cochlear share price is 20% lower than its February high. Here's why I think it might be a good buying opportunity for investors today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) shares have not had a good year in 2020 so far. After topping out at a new (and still standing) all-time high of $251.55 back in February, the Cochlear share price is today asking just $200.50 at the time of writing. That's more than a 20% discount to the February high watermark. Now just because a share has pulled back 20% from its most recent high, this does not mean it's automatically 'on sale' or a 'good deal'. But it does merit some digging in my view, particularly when the company in question is as high calibre as Cochlear.

cheap cochlear share price represented by large green letters spelling out twenty percent

Image source: Getty images

Lend me your ears…

Cochlear is one of the most successful ASX shares in the healthcare space. It famously pioneered the 'Cochlear implant' – a hearing aid device now universally recognisable. The company has continued to remain in the vanguard of hearing aid technology and is still a market leader in the space. It now has a truly global presence, with 20% of its sales now coming from emerging markets. It holds a 60% share of its global product market.

However, like many ASX companies, both Cochlear and its shares have been under pressure this year due to the coronavirus pandemic. In its FY2020 earnings report released last month, Cochlear reported a loss of $238.3 million for the year on revenues of $1.35 billion, mostly due to surgery deferrals as a result of the pandemic. As such, the company will not be paying a final dividend in 2020.

Why is the Cochlear share price a buy today then?

I think Cochlear is worth a good look today, even after its disappointing earnings report. Yes, Cochlear has taken a massive hit this year. But the market that it serves (people with a hearing impairment) hasn't gone anywhere. Cochlear serves a large customer base with inelastic demand for its products. Many of the company's patients are born with a hearing impairment, which means they have a fair chance of being Cochlear customers for life. The company already has a dominant position in advanced economies around the world and as incomes rise in emerging markets, more and more potential customers are finding Cochlear as well.

As such, I think the pullback we've seen in the Cochlear share price this year presents a solid buying opportunity. Quality companies like Cochlear don't go on sale often, and so I think this is a rare chance to open a position or double-down if you already have one.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people push and shove through the doors of a store, trying to beat the crowd.
Share Market News

Investors are buying CSL shares again. Should you?

Some experts believe that 2026 could mark the low point for the biotech company.

Read more »

A group of young people celebrate and party outside.
Healthcare Shares

If I'd invested $5,000 in 4DMedical shares 12 months ago, guess how much I'd have now!

Can the company's share price keep accelerating even higher? Here's what analysts tip for the next 12 months.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 reasons I'd buy CSL shares in FY27

It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

CSL shares jump 15%: Is it time to start buying the beaten-down biotech stock?

CSL shares have climbed 7% higher over the past week alone.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why is this ASX biotech rocketing more than 20%?

A deal potentially worth hundreds of millions has been struck.

Read more »

Young girl shows hearing aid while smiling.
Healthcare Shares

3 reasons to buy Cochlear shares in June

After a brutal sell-off, the stock may be gearing up for a recovery.

Read more »

patient with doctor, medical company, medical insurance
Cheap Shares

CSL shares trade at just 12 times forecast earnings. Here's why they could be the buy of the decade

The ASX 200 healthcare giant is down more than 60% since August 2025.

Read more »

Falling pills in a blue background.
Healthcare Shares

Sigma Healthcare shares are surging. What does Macquarie say they're worth?

A possible deal has fallen over, which investors appear to like.

Read more »